Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors [0.03%]
纵向甲基化ctDNA的增加可预测实体瘤免疫治疗的进展
Muhammad Anees,Patrick L Wagner,Ashten Omstead et al.
Muhammad Anees et al.
Timely identification of treatment failure during immune checkpoint blockade remains a critical unmet need in oncology. We evaluated a tissue-free, methylation-based circulating tumor DNA (ctDNA) assay applied serially across 142 patients w...
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461] [0.03%]
关于“液态活检在组织分子检测基础上评估转移性非小细胞肺癌患者初始价值的增量”一文的勘误注释
Benjamin A Bleiberg,Dylan G Scholes,Lauren Reed-Guy et al.
Benjamin A Bleiberg et al.
[This corrects the article DOI: 10.1016/j.jlb.2026.100461.]. © 2026 The Author(s).
Published Erratum
The journal of liquid biopsy. 2026 May 7:12:100472. DOI:10.1016/j.jlb.2026.100472 2026
Shivahamy Maheswaran,Canio Martinelli,Diego de Miguel Perez et al.
Shivahamy Maheswaran et al.
Cancer in a drop: Liquid biopsy highlights from the San Antonio Breast Cancer Symposium (SABCS) 2025 [0.03%]
肿瘤与液体活检：2025圣安东尼奥乳腺癌研讨会亮点回顾
Eleonora Nicolò,Konstantinos Venetis,Enes Erul et al.
Eleonora Nicolò et al.
Breaking news from ESMO 2025: liquid biopsy novelties in gastrointestinal cancer [0.03%]
ESMO 2025年会最新消息：消化道肿瘤液体活检新进展
Serena Pillozzi,Giulia Petroni,Daniele Lavacchi et al.
Serena Pillozzi et al.
Liquid biopsy (LB) has emerged as a minimally invasive approach to characterize tumor biology and support treatment decision-making across gastrointestinal (GI) malignancies. Advances in circulating biomarkers have expanded its potential cl...
Development of a LiDia-SEQ™ platform compatible breast cancer panel and testing with metastatic breast cancer patient samples: A rapid, sample-to-result, fully integrated next-generation sequencing (NGS)-based platform, LiDia-SEQ, for use at the point-of-need [0.03%]
开发一种LiDia-SEQ™平台兼容的乳腺癌检测板，并使用转移性乳腺癌患者样本进行测试：这是一种快速、从样品到结果的、基于下一代测序（NGS）的、完全集成的用于即时检测的LiDia-SEQ平台
Mohammadali Yavari Ramsheh,Raquel L Fraccari,Rossitza Christova et al.
Mohammadali Yavari Ramsheh et al.
Background: Plasma circulating tumour DNA (ctDNA) analysed using next generation sequencing (NGS) reflects the evolving tumour molecular landscape. However, barriers to routine adoption of NGS ctDNA analysis in clinical s...
Sima Singh,Ada Raucci,Antonella Miglione et al.
Sima Singh et al.
Liquid biopsy has emerged as a powerful approach for tracking tumor dynamics through circulating biomarkers such as cell-free tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), microRNAs (miRNAs) and soluble pr...
Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib [0.03%]
探索纵向系列p.G12C KRAS突变NSCLC患者使用sotorasib治疗的基因组分析和甲基化谱特征
Francesco Pepe,Francesco Passiglia,Claudia Scimone et al.
Francesco Pepe et al.
in the genomic era, the advent of next generation sequencing (NGS) technologies has rapidly transformed the clinical paradigm of NSCLC patients who could benefit from a wide series of clinically approved biomarker driven therapies. Among th...
Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC [0.03%]
基于CT影像组学和液体活检的放射基因组综合方法可改善晚期肺腺癌患者的预后分层研究
Alberto Ranghiero,Lisa Rinaldi,Sofia Netti et al.
Alberto Ranghiero et al.
Background: Radiomics and liquid biopsy represent minimally invasive approaches to assess disease characteristics in solid tumors. We integrated computed tomography (CT) radiomics and circulating tumor DNA (ctDNA) analysi...
Exploring tear biomarkers with shotgun proteomics for retinoblastoma diagnosis: a pilot study [0.03%]
基于泪液的白蛋白组学研究在视网膜母细胞瘤诊断中的应用：一项前瞻性队列研究报告
Andrés Rodríguez-Rodríguez,Karla Grisel Calderón-González,Juan Pedro Luna-Arias et al.
Andrés Rodríguez-Rodríguez et al.
The most common ocular neoplasia among children is retinoblastoma. Currently, the diagnosis of this disease is essentially clinical, taking a biopsy is contraindicated owing to the high risk of causing metastasis. Therefore, it is imperativ...